New research is showing that a class of medications originally developed for diabetes — GLP-1s — may help quiet the relentless "wanting" associated with addiction. Semaglutide trials have found reductions in alcohol craving; research on other substances is still emerging. Not a replacement for treatment. A potential tool to discuss alongside it.
Your brain built one “wanting” system — and GLP-1 medications may turn that signal down at its source.
Food and addictive substances engage overlapping brain reward systems. GLP-1 receptors are found in regions involved in reward processing. Preclinical work and emerging human studies suggest these pathways may help explain changes in craving. The mechanism and effects across different substances are still being studied.
People taking GLP-1s for weight loss started reporting something unexpected: less interest in alcohol, cigarettes, and more. Researchers took notice. Randomized trials have now tested effects on alcohol use directly; research on other substances is still emerging.
A potential tool to discuss alongside treatment. Keep your recovery team involved, and bring your goals, current medications, and support plan into the conversation.
In a randomized clinical trial, weekly low-dose semaglutide reduced alcohol craving and drinks per drinking day versus placebo over 9 weeks.
A 26-week trial in people with alcohol use disorder and obesity found reductions in drinking with semaglutide alongside cognitive behavioral therapy. These results apply to the population studied.
In a cohort of 600,000+ veterans with type 2 diabetes, GLP-1 use was associated with 40% lower overdose risk among those with existing substance use disorders. Observational results do not prove prevention or predict an individual outcome.
The randomized trials are small to mid-sized; the largest outcome data is observational and shows association, not proof. GLP-1 medications are not FDA-approved for addiction. These findings do not promise craving relief, relapse prevention, or benefits for every substance use disorder.
Semaglutide acts on the GLP-1 receptor. Certain FDA-approved semaglutide products are used for weight management in eligible patients. The formulation offered, eligibility, and treatment plan must be confirmed during your clinical evaluation.
Share your health history and goals, including your recovery care and current medications. Complete the Soberpedia intake before checkout.
A licensed clinician must review your case and assess risks before any treatment decision. This page does not confirm that off-label addiction treatment is available through this service.
If prescribed, the exact medication, formulation, dose, pharmacy, and availability must be confirmed by the care team. An assessment does not guarantee a prescription or supply.
No. Treatment depends on a clinician’s evaluation, product availability, and pharmacy requirements.
Your Start intake button opens Soberpedia’s care portal (powered by Superstar Wellness LLC) with Semaglutide selected. The intake comes first; review all charges before submitting payment.
That has not been established as an approved use. Early alcohol research is a reason for further study, not a promise of craving relief or relapse prevention. Ask your addiction clinician about established treatments and whether any additional evaluation is appropriate.
Share your recovery goals, substance-use history, current treatment, medications, nutrition concerns, and other health conditions. Ask about evidence, risks, alternatives, and the exact formulation being considered.
If the constant pull is the hardest part of your recovery, start a conversation with your clinician about the evidence and your individual needs. Keep your existing recovery support close. This is not detox or withdrawal management and does not replace prescribed addiction treatment.
Find addiction treatment through Soberpedia →PRODUCT INFORMATION
Answers from this product’s published information. General information, not medical advice. Please leave out personal medical details.
Continue exploring
Soberpedia
